SYHA1815
SYHA1815 is an orally active RET inhibitor (IC50=0.9 nmol/L) with antitumor activity. SYHA1815 is more selective for RET than KDR (IC50=15.9 nmol/L) . SYHA1815 arrests the G1 cell cycle and inhibits RET-driven cell proliferation by downregulating c-Myc[1].
Product Specifications
CAS Number
2760195-67-1
UNSPSC
12352005
Target
C-Myc; RET; VEGFR
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/syha1815.html
Smiles
CN(CC1)CCN1CC2=C(C(F)(F)F)C=C(NC(C3=CC(F)=CC(C#CC4=CC=CN=C4N)=C3)=O)C=C2.Cl
Molecular Formula
C27H26ClF4N5O
Molecular Weight
547.97
References & Citations
[1]Yuchen Jiang, et al. "The novel RET inhibitor SYHA1815 inhibits RET-driven cancers and overcomes gatekeeper mutations by inducing G1 cell-cycle arrest through c-myc downregulation." Molecular Cancer Therapeutics 20.11 (2021) : 2198-2206.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GP-1104-20 1 mL
Colloidal Gold Conjugated Canavalia ensiformis Lectin (Jackbean) -Con A-, 20nm
Sign In for Pricing
View Details ![MTRF1L Mouse Monoclonal Antibody (HRP conjugated) [Clone ID: OTI1D11]](https://cdn.genprice.uk/products/937/68dd1b65061270361ea143be/imageurl/ta501004bm.webp)
TA501004BM 100 µL
MTRF1L Mouse Monoclonal Antibody (HRP conjugated) [Clone ID: OTI1D11]
Sign In for Pricing
View Details 
TRC-D957525-25MG 25 mg
11beta,20beta-Dihydroxy-3-oxopregn-4-en-21-oic acid
Sign In for Pricing
View Details 
BNC402115-500 1x 500 µL
Cytokeratin 8 (KRT8) (KRT8/2115), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details